BackF-star Therapeutics Overview

F-star Therapeutics Total Current Liabilities

F-star Therapeutics's total current liabilities is $15M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$14.68M
66.10% YoYΔ $5.84M vs prior year quarter

Peer average

Loading

F-star Therapeutics Total Current Liabilities History

Loading

F-star Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

F-star Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

F-star Therapeutics (FSTX) FAQ

F-star Therapeutics's total current liabilities stands at $15M as of September 2022. That compares with $8.8M in the prior-year period — up 66.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

F-star Therapeutics reported $15M in total current liabilities versus $8.8M a year earlier — a 66.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $8.8M in the prior-year period — up 66.1% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how F-star Therapeutics's total current liabilities evolved across reporting periods, while the comparison chart places FSTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. F-star Therapeutics's reading of $15M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.